Preclinical research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-06. Anything still debated is marked as such rather than presented as settled.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Metalloprotein is a generic term for a protein that contains a metal ion cofactor. A large proportion of all proteins are part of this category. For instance, at least 1000 human proteins (out of ~20,000) contain zinc-binding protein domains although there may be up to 3000 human zinc metalloproteins.
=== Towards a "physical eschatology" === The knowledge of these hypothetical supercivilizations must fit into a wide range of physical laws that contain the entirety of our current knowledge, since the technical and scientific developments of mankind can be considered as an inevitable and necessary stage in the process of the evolution of a civilization. Based on this principle, Kardashev proposes to define several concepts applicable to extraterrestrial civilizations. The physical laws, which are universal, can be used as a common basis for understanding other civilizations and, in particular, allow us to develop an objective research program. Michio Kaku also believes that the evolution of civilizations obeys the "iron laws of physics" and in particular the laws of thermodynamics, those of stable matter (baryonic matter) and those of planetary evolution (probability of occurrence of natural or cosmic catastrophes). The anthropic principle also makes it possible to predict the sociological characteristics at the basis of any civilization. However, these universal laws are not the only parameters to consider. Zoltan Galántai explains that "it is impossible to calculate the future of the Universe over long periods of time without including the effects of life and intelligence", a position close to that of Freeman Dyson. Taking into account these two phenomena, the universal physical laws and the intelligence resulting from life, defines a "physical eschatology", as Galántai puts it.
Hypermobility spectrum disorders (HSD) are a group of heritable connective tissue disorders where joints are flexible enough to cause problems such as instability and pain. Different forms and sub-types have been distinguished, but it does not include asymptomatic joint hypermobility, colloquially known as double-jointedness, nor does it include Ehlers–Danlos syndromes. This condition was called "joint hypermobility syndrome" (JHS) until 2017, when it was renamed and subtypes were defined. There is a strong association between HSD and neurodevelopmental disorders such as attention deficit hyperactivity disorder and autism spectrum disorder.
These elements can be then identified simply based on their elution position/time, using α-hydroxyisobutyrate solution (α-HIB), for example, as eluant. The 3+ actinides can also be separated via solvent extraction chromatography, using bis-(2-ethylhexyl) phosphoric acid (abbreviated as HDEHP) as the stationary organic phase, and nitric acid as the mobile aqueous phase. The actinide elution sequence is reversed from that of the cation-exchange resin column. The einsteinium separated by this method has the advantage to be free of organic complexing agent, as compared to the separation using a resin column.
Sources: en.wikipedia.org
These trans-containing isomers separate chromatographically from cis-containing isomers and have the tendency to co-elute with each other and, in some cases, with select C20:1 isomers. GC-VUV is not only able to differentiate the C18:3 FAME variants, but is also capable of telling cis isomers apart from trans isomers. Degrees of unsaturation such as C20:1 vs. C18:3 can additionally be distinguished. Previous work has demonstrated how distinct VUV spectra enable straightforward deconvolution and accurate quantitation of cis and trans FAME isomers.
The prime recovery ship was USS Wasp. The recovery was supported by 10,249 U.S. Department of Defense personnel, 134 aircraft, and 26 ships. Postflight medical examination found the astronauts to be in good health, and no significant physiological changes were found.
Nickel is a silvery-white metal with a slight golden tinge that takes a high polish. It is one of only four elements that are ferromagnetic at or near room temperature; the others are iron, cobalt and gadolinium. Its Curie temperature is 355 °C (671 °F), meaning that bulk nickel is non-magnetic above this temperature. The unit cell of nickel is a face-centered cube; it has lattice parameter of 0.352 nm, giving an atomic radius of 0.124 nm. This crystal structure is stable to pressures of at least 70 GPa. Nickel is hard, malleable and ductile, and has a relatively high electrical and thermal conductivity for transition metals. The high compressive strength of 34 GPa, predicted for ideal crystals, is never obtained in the real bulk material due to formation and movement of dislocations. However, it has been reached in Ni nanoparticles.
=== Celebrity Big Brother === In January 2006, Galloway appeared on the fourth series of the reality TV programme Celebrity Big Brother for nearly three weeks. During his time on the programme, he mimed licking imaginary milk, whilst pretending to be a cat, from the cupped hands of another housemate, actress Rula Lenska. He wrote later that his activities "were actually the same stunts that BBC presenters and celebs get up for Children in Need". Galloway faced a claim at the time from Hilary Armstrong, Labour's Chief Whip, that he should "respect his constituents, not his ego". Ron McKay, his spokesman and friend, said of the imaginary milk incident: "I rather wish he hadn't been given that particularly silly task". It had been assumed, McKay said, that Galloway's comments about politics would not be cut. Just after his eviction, Galloway told presenter Davina McCall he was positive about having taken part, although when asked if he was "glad" to have participated, he said: "Not after I've seen those press cuttings." Galloway wrote in a column for The Independent newspaper in November 2012 that his "antics on Big Brother" had "raised tens of thousands of pounds for the charity Interpal" and paid for an "extra caseworker in my constituency".
==== Allosteric regulator ==== Acetyl-CoA serves as an allosteric regulator of pyruvate dehydrogenase kinase (PDK). It regulates through the ratio of acetyl-CoA versus CoA. Increased concentration of acetyl-CoA activates PDK. Acetyl-CoA is also an allosteric activator of pyruvate carboxylase.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.